Literature DB >> 20975572

Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange.

Wei-lin Mao1, Yu Chen, Yue-mei Chen, Lan-juan Li.   

Abstract

BACKGROUND AND AIM: Acute on chronic liver failure (AoCLF) is associated with a high mortality rate. Plasma exchange (PE) may be useful to bridge patients with AoCLF to liver transplantation or to regenerate their own livers. The aim of this study was to assess the effects of PE on the circulating concentrations of cytokines in patients with AoCLF.
METHODS: One hundred forty-nine patients with AoCLF in 2 groups (PE plus routine-care, n=62; and routine-care, n=87) were enrolled in our study. Fifteen healthy donors were used as the control group. Cytokine levels such as interferon-γ (IFN-γ), interleukin-10 (IL-10), interleukin-4 (IL-4), interleukin-2 (IL-2), and tumor necrosis factor- α (TNF-α) were detected on admission and on days 7, 14, 21, and 30 during hospitalization.
RESULTS: All the detected cytokine values (IFN-γ, IL-10, IL-4, IL-2, and TNF-α) in the patient groups were higher compared with those in the healthy controls (P<0.001). PE was effective to decrease the serum concentration of cytokines: TNF-α dropped from (3.46±1.23) pg/mL to (1.64±0.66) pg/mL (P<0.01), IL-10 from (6.2±2.1) pg/mL to (3.5±1.1) pg/mL (P<0.01), IL-2 from (7.5±4.7) pg/mL to (4.0±2.1) pg/mL (P<0.01), IFN-γ from (27.5±15.8) pg/mL to (15.5±11.8) pg/mL (P<0.01), and IL-4 from (86.7±31.3) pg/mL to (44.7±26.3) pg/mL (P<0.01).
CONCLUSIONS: Cytokines may be important in the pathogenesis of the AoCLF, and PE may represent a reliable hepatic support device for AoCLF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20975572     DOI: 10.1097/MCG.0b013e3181faefa3

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  Plasma exchange for acute on chronic liver failure: is there a light at the end of the tunnel?

Authors:  Rakhi Maiwall; Richard Moreau
Journal:  Hepatol Int       Date:  2016-02-04       Impact factor: 6.047

2.  Changes in peripheral CD4+CD25(high) regulatory T cells in the acute-on-chronic liver failure patients with plasma exchange treatment.

Authors:  Wei-lin Mao; Yu-Feng Lou; Bo Ye; Sha Lin; Yue-mei Chen; Yu Chen
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

3.  Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B.

Authors:  YuFeng Lou; ManYi Wang; WeiLin Mao
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

4.  Ascitic Bacterial Composition Is Associated With Clinical Outcomes in Cirrhotic Patients With Culture-Negative and Non-neutrocytic Ascites.

Authors:  Yanfei Chen; Jing Guo; Ding Shi; Daiqiong Fang; Chunlei Chen; Lanjuan Li
Journal:  Front Cell Infect Microbiol       Date:  2018-11-30       Impact factor: 5.293

5.  Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure.

Authors:  Sandeep Satsangi; Ajay Duseja; Meenakshi Sachdeva; Shallu Tomer; Sunil K Arora; Sunil Taneja; Radha K Dhiman; Yogesh K Chawla
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

6.  Plasma Interleukin-6 Level: A Potential Prognostic Indicator of Emergent HBV-Associated ACLF.

Authors:  Zhe-Bin Wu; Yu-Bao Zheng; Ke Wang; Zhi-Shuo Mo; Xu Zhen; Ying Yan; Zhi-Liang Gao
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-11

7.  Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection.

Authors:  Sha Lin; QinQin Sun; WeiLin Mao; Yu Chen
Journal:  Gastroenterol Res Pract       Date:  2016-03-30       Impact factor: 2.260

8.  Nomogram based on blood lipoprotein for estimation of mortality in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Cuicui Xiao; Jiao Gong; Shuguang Zhu; Zhiwei Zhang; Sujuan Xi; Yutian Chong; Yusheng Jie; Qi Zhang
Journal:  BMC Gastroenterol       Date:  2020-06-15       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.